{
  "id": "mhgap#risk_safety_a6a00376",
  "content": "mania), carefully balancing effectiveness, side-effects and individual preference.\nStrong recommendation. Low certainty of evidence.\n7.2 Valproic acid (sodium valproate) should not be used in women and girls of childbearing\npotential, owing to the high risk of birth defects and neurodevelopmental disorders in\nbabies in utero.\nStrong recommendation. Low certainty of evidence.\nPSY8 (update) 8.1 Mood stabilizers (namely carbamazepine, lithium, valproic acid [sodium valproate])\nor oral antipsychotic medicines (namely aripiprazole, olanzapine, quetiapine) should\nbe considered for maintenance treatment for adults with bipolar disorder in remission,\ncarefully balancing effectiveness, side-effects and individual preference.\nConditional recommendation. Low certainty of evidence.\n8.2 Valproic acid (sodium valproate) should not be used in women and girls of childbearing\npotential with bipolar disorder in remission, owing to the high risk of birth defects and\nneurodevelopmental disorders in babies in utero.\nStrong recommendation. Low certainty of evidence.\nxxix\nMental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders\nTABLE 1. (continued) Summary of recommendations\nModule and Recommendation\nrecommendation\nStrength of the recommendation and certainty of the evidence\nnumber\nPSY9 (update) Fluoxetine, olanzapine, quetiapine, valproic acid (sodium valproate) or venlafaxine should\nbe considered for adults with bipolar depression. If fluoxetine or venlafaxine are chosen,",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "risk_safety",
      "referral",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General â€” Risk Safety mania), carefully balancing effectiveness, side-effects and individual preference.\nStrong recommendation. Low certainty of evidence.\n7.2 Valproic acid (sodium valproate) should not be used in women and girls of childbearing\npotential, owing to the high risk of birth defects and neurodevelopmental disorders in\nbabies in utero.\nStrong recommendation. Low certainty of evidence.\nPSY8 (update) 8.1 Mood stabilizers (namely carbamazepine, lithium, valproic acid [sodium valproate])\nor oral antipsychotic medicines (namely aripiprazole, olanzapine, quetiapine) should\nbe considered for maintenance treatment for adults with bipolar disorder in remission,\ncarefully balancing effectiveness, side-effects and individual preference.\nConditional recommendation. Low certainty of evidence.\n8.2 Valproic acid (sodium valproate) should not be used in women and girls of childbearing\npotential with bipolar disorder in remission, owing to the high risk of birth defects and\nneurodevelopmental disorders in babies in utero.\nStrong recommendation. Low certainty of evidence.\nxxix\nMental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders\nTABLE 1. (continued) Summary of recommendations\nModule and Recommendation\nrecommendation\nStrength of the recommendation and certainty of the evidence\nnumber\nPSY9 (update) Fluoxetine, olanzapine, quetiapine, valproic acid (sodium valproate) or venlafaxine should\nbe considered for adults with bipolar depression. If fluoxetine or venlafaxine are chosen, Mania), carefully balancing effectiveness, side-effects and individual preference. strong recommendation."
}